A Randomized, Double-blind, Placebo-controlled, Dose Escalation Phase 1 Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics Characteristics of NTQ5082 Capsules Orally Administered in Healthy Volunteers in Single and Multiple Doses
Latest Information Update: 27 Aug 2024
At a glance
- Drugs NTQ 5082 (Primary)
- Indications Haematological disorders
- Focus Adverse reactions
- Sponsors Nanjing Chia Tai Tianqing Pharmaceutical
Most Recent Events
- 27 Aug 2024 New trial record